IL17A and gout: A recent randomized, double-blind, placebo-controlled pilot study showed a positive correlation between UA serum levels and IL-6, IL-17, and TNF-α, suggesting that xanthine oxidase inhibitors reduce levels of serum UA but also of these cytokines in patients with gout (42).